NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Co
Go back to NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Co| NAMSCO Corporation (NASDAQ: NAMS) | Delayed: 26.79 -0.61 (2.23%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.40 | 52 Week High | $0.00 | |||
| Open | $27.15 | 52 Week Low | $0.00 | |||
| Day High | $27.60 | P/E | N/A | |||
| Day Low | $26.67 | EPS | $0.00 | |||
| Volume | 626,831 | |||||
